Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a EoE Trial Data, Highlighting Strong Symptom Response
EPRX has more than doubled off its 52-week low of $2.68 on elevated volume (2.7× avg).
Summary
Eupraxia Pharmaceuticals reported positive 24-week symptom data from its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis, showing strong clinical remission rates and a favorable safety profile for EP-104GI.
Key Events · Product Development and Regulatory · EPRX
-
Positive Symptom Data from Highest Dose Cohort
Patients in the highest dose cohort (n=3) of the Phase 1b/2a RESOLVE trial achieved an average 4-point reduction in symptom scores at 24 weeks, exceeding the 3-point threshold for clinical remission.
-
High Clinical Remission Rates Maintained
Pooled data from dose cohorts 4-9 indicated that 76% (13/17) of patients maintained clinical remission at 24 weeks, and 67% (6/9) maintained it at 52 weeks.
-
Improved Drug Delivery Re-establishes Dose-Response
The adoption of larger 19-gauge catheters for the 6 mg/site dose (Cohort 8b) significantly improved outcomes, including SDI reduction and peak eosinophil reduction, compared to previous catheter use, re-establishing the dose-response relationship.
-
Strong Safety and Tolerability Profile
Over 220 patient-months of follow-up across 31 patients reported no Serious Adverse Events (SAEs) or cases of oropharyngeal candidiasis, a common adverse event with oral steroids.
Analysis · EPRX · Life Sciences
Eupraxia Pharmaceuticals announced positive 24-week symptom data from the highest dose cohort of its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis (EoE). The data shows a meaningful symptom response and high rates of clinical remission, which is critical for a clinical-stage biotechnology company. The improved drug delivery with new catheters and the continued strong safety profile further de-risk the EP-104GI program and provide a positive signal for the ongoing placebo-controlled Phase 2b trial, with top-line data anticipated in Q3 2026. This positive clinical update follows recent news of an extended cash runway and increased insider ownership, creating a favorable near-term narrative for the company.
At the time of this filing, EPRX was trading at $7.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $454.5M. The 52-week trading range was $2.68 to $9.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.